Most-Downgraded StocksMost-Downgraded Alnylam Pharmaceuticals Stock Price, News & Analysis (NASDAQ:ALNY) $172.87 +1.46 (+0.85%) (As of 12/4/2023 ET) Add Compare Share Share Today's Range$169.77▼$173.4950-Day Range$151.41▼$178.9652-Week Range$148.10▼$242.97Volume387,361 shsAverage Volume674,331 shsMarket Capitalization$21.69 billionP/E RatioN/ADividend YieldN/APrice Target$233.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Alnylam Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.68 Rating ScoreUpside/Downside34.8% Upside$233.00 Price TargetShort InterestHealthy4.14% of Shares Sold ShortDividend StrengthN/ASustainability-1.52Upright™ Environmental ScoreNews Sentiment1.22Based on 10 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($3.74) to ($5.15) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.54 out of 5 starsMedical Sector138th out of 952 stocksPharmaceutical Preparations Industry50th out of 434 stocks 4.3 Analyst's Opinion Consensus RatingAlnylam Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.68, and is based on 13 buy ratings, 6 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $233.00, Alnylam Pharmaceuticals has a forecasted upside of 34.8% from its current price of $172.87.Amount of Analyst CoverageAlnylam Pharmaceuticals has been the subject of 10 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 3.0 Short Interest Percentage of Shares Shorted4.14% of the outstanding shares of Alnylam Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverAlnylam Pharmaceuticals has a short interest ratio ("days to cover") of 8.Change versus previous monthShort interest in Alnylam Pharmaceuticals has recently decreased by 1.52%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldAlnylam Pharmaceuticals does not currently pay a dividend.Dividend GrowthAlnylam Pharmaceuticals does not have a long track record of dividend growth. Previous Next 4.3 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreAlnylam Pharmaceuticals has received a 63.92% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is false driven by its "Gene therapy medication", "Clinical research services", and "Preclinical research services" products. See details.Environmental SustainabilityThe Environmental Impact score for Alnylam Pharmaceuticals is -1.52. Previous Next 3.5 News and Social Media Coverage News SentimentAlnylam Pharmaceuticals has a news sentiment score of 1.22. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.76 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 10 news articles for Alnylam Pharmaceuticals this week, compared to 8 articles on an average week.Search InterestOnly 5 people have searched for ALNY on MarketBeat in the last 30 days. This is a decrease of -44% compared to the previous 30 days.MarketBeat Follows3 people have added Alnylam Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Alnylam Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 1.40% of the stock of Alnylam Pharmaceuticals is held by insiders.Percentage Held by Institutions93.98% of the stock of Alnylam Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Alnylam Pharmaceuticals are expected to decrease in the coming year, from ($3.74) to ($5.15) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Alnylam Pharmaceuticals is -41.76, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Alnylam Pharmaceuticals is -41.76, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next See Top Rated MarketRank™ Stocks Here About Alnylam Pharmaceuticals Stock (NASDAQ:ALNY)Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system (CNS)/ocular diseases. Its marketed products include ONPATTRO (patisiran), a lipid complex injection for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria (AHP); and OXLUMO (lumasiran) for the treatment of primary hyperoxaluria type 1 (PH1). In addition, the company is developing givosiran for the treatment of adolescent patients with AHP; patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; ALN-AAT02 for the treatment of AAT deficiency-associated liver disease; ALN-HBV02 to treat chronic HBV infection; Zilebesiran to treat hypertension; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia and rare bleeding disorders, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1 and recurrent renal stones, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Sanofi Genzyme to discover, develop, and commercialize RNAi therapeutics. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.Read More ALNY Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ALNY Stock News HeadlinesDecember 4, 2023 | au.investing.comPro Research: Wall Street delves into Alnylam PharmaceuticalsDecember 2, 2023 | americanbankingnews.comAlnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Receives Consensus Rating of "Moderate Buy" from AnalystsDecember 4, 2023 | Wealthpress (Ad)Trading Experts Call It “The Perfect Tesla Trade”Thanks to a new discovery linked to shares of Tesla, regular folks can now target gains of 100% or more in six days or less. New research shows it’s happened 23 different times this year. The next trade is scheduled for this Thursday.December 1, 2023 | markets.businessinsider.comAnalysts Are Bullish on These Healthcare Stocks: UnitedHealth (UNH), Alnylam Pharma (ALNY)November 30, 2023 | finance.yahoo.comAlnylam Ranks #1 on Boston Globe’s Top Places to Work List for 2023November 29, 2023 | benzinga.comAlnylam Pharmaceuticals Stock (NASDAQ:ALNY) Dividends: History, Yield and DatesNovember 29, 2023 | msn.comAlnylam Pharmaceuticals tops list of largest companies for the third yearNovember 15, 2023 | markets.businessinsider.comPromising Future for Milestone Pharmaceuticals: Buy Rating Reaffirmed Amid Encouraging Etripamil Trial Outcomes and Projected Revenue GrowthDecember 4, 2023 | Wealthpress (Ad)Trading Experts Call It “The Perfect Tesla Trade”Thanks to a new discovery linked to shares of Tesla, regular folks can now target gains of 100% or more in six days or less. New research shows it’s happened 23 different times this year. The next trade is scheduled for this Thursday.November 13, 2023 | seekingalpha.comAlnylam: Q3 Journey, Financial Growth, And Regulatory HurdlesNovember 13, 2023 | markets.businessinsider.comAnalysts Conflicted on These Healthcare Names: Exelixis (EXEL), Hologic (HOLX) and Alnylam Pharma (ALNY)November 13, 2023 | msn.comAlnylam reports positive Phase 2 data for hypertension drugNovember 11, 2023 | businesswire.comAlnylam Presents Positive Results from the KARDIA-1 Phase 2 Dose-Ranging Study of Zilebesiran, an Investigational RNAi Therapeutic in Development for the Treatment of ...November 11, 2023 | finance.yahoo.comAlnylam Presents Positive Results from the KARDIA-1 Phase 2 Dose-Ranging Study of Zilebesiran, an Investigational RNAi Therapeutic in Development for the Treatment of Hypertension in Patients at High Cardiovascular RiskNovember 10, 2023 | markets.businessinsider.comOppenheimer Keeps Their Hold Rating on Teva Pharmaceutical (TEVA)November 9, 2023 | finance.yahoo.comAlnylam Pharmaceuticals, Inc.: Alnylam Earnings: Strong Demand for Amvuttra Drives Sales; Shares UndervaluedNovember 8, 2023 | finance.yahoo.comWall Street Analysts Think Alnylam (ALNY) Could Surge 35.08%: Read This Before Placing a BetNovember 6, 2023 | markets.businessinsider.comHold Rating on Alnylam Pharma: Q3 Performance, Pipeline Prospects, and Regulatory ChallengesNovember 6, 2023 | markets.businessinsider.comAlnylam Pharma: Promising Revenue and Pipeline Updates Inspire Buy Rating Despite Lowered Price TargetNovember 4, 2023 | finance.yahoo.comAlnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Q3 2023 Earnings Call TranscriptNovember 4, 2023 | markets.businessinsider.comAnalysts Are Bullish on These Healthcare Stocks: Alnylam Pharma (ALNY), COMPASS Pathways (CMPS)November 4, 2023 | markets.businessinsider.comBuy Rating for Alnylam Pharma: Key Catalysts and Promising Pipeline ProgramsNovember 2, 2023 | markets.businessinsider.comAlnylam Pharmaceuticals Inc. Q3 Earnings SummaryNovember 2, 2023 | msn.comAlnylam Pharmaceuticals beats Q3 top and bottom line estimates; updates FY23 outlookNovember 2, 2023 | finance.yahoo.comAlnylam (ALNY) Q3 Earnings: Taking a Look at Key Metrics Versus EstimatesNovember 2, 2023 | finance.yahoo.comAlnylam Pharmaceuticals Inc (ALNY) Reports 35% YoY Growth in Q3 2023 Net Product RevenuesNovember 2, 2023 | seekingalpha.comAlnylam Pharmaceuticals, Inc. 2023 Q3 - Results - Earnings Call PresentationSee More Headlines Receive ALNY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Alnylam Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/02/2023Today12/04/2023Fiscal Year End12/31/2023Next Earnings (Estimated)2/22/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryBiotechnology SectorMedical Current SymbolNASDAQ:ALNY CUSIP02043Q10 CIK1178670 Webwww.alnylam.com Phone(617) 551-8200Fax617-551-8101Employees2,002Year Founded2002Price Target and Rating Average Stock Price Target$233.00 High Stock Price Target$395.00 Low Stock Price Target$143.00 Potential Upside/Downside+34.8%Consensus RatingModerate Buy Rating Score (0-4)2.68 Research Coverage19 Analysts Profitability EPS (Most Recent Fiscal Year)($4.14) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-1,131,160,000.00 Net Margins-29.58% Pretax Margin-29.17% Return on EquityN/A Return on Assets-14.38% Debt Debt-to-Equity RatioN/A Current Ratio3.14 Quick Ratio3.04 Sales & Book Value Annual Sales$1.04 billion Price / Sales20.91 Cash FlowN/A Price / Cash FlowN/A Book Value($1.29) per share Price / Book-134.01Miscellaneous Outstanding Shares125,490,000Free Float123,736,000Market Cap$21.69 billion OptionableOptionable Beta0.50 Social Links 12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?Get This Free Report Key ExecutivesDr. Yvonne L. Greenstreet M.B.A. (Age 60)MBChB, CEO & Director Comp: $2.09MMr. Jeffrey V. Poulton M.B.A. (Age 55)CFO & Executive VP Comp: $972.35kMs. Indrani M. Lall Franchini J.D. (Age 51)Executive VP, Chief Legal Officer & Secretary Comp: $958.96kDr. Akshay K. Vaishnaw M.D. (Age 60)Ph.D., Chief Innovation Officer Comp: $1.24MDr. Pushkal P. Garg M.D. (Age 55)Chief Medical Officer and Executive VP of Development & Medical Affairs Comp: $1MMr. Timothy J. MainesChief Technical Operations & Quality OfficerDr. Kevin Joseph Fitzgerald Ph.D. (Age 55)Senior VP, Head of Research & Chief Scientific Officer Ms. Christine Regan Lindenboom (Age 42)Senior VP of Investor Relations & Corporate Communications Mr. Piyush Sharma J.D.Chief Ethics & Compliance OfficerMr. Evan LippmanChief Corporate Development & Strategy OfficerMore ExecutivesKey CompetitorsBioMarin PharmaceuticalNASDAQ:BMRNUnited TherapeuticsNASDAQ:UTHRIonis PharmaceuticalsNASDAQ:IONSGenmab A/SNASDAQ:GMABBeiGeneNASDAQ:BGNEView All CompetitorsInsiders & InstitutionsWellington Management Group LLPBought 364,021 shares on 12/1/2023Ownership: 5.125%American Century Companies Inc.Bought 3,872 shares on 11/30/2023Ownership: 0.353%Banque Pictet & Cie SASold 1,154 shares on 11/27/2023Ownership: 0.020%Deutsche Bank AGSold 24,020 shares on 11/24/2023Ownership: 0.369%EP Wealth Advisors LLCBought 71 shares on 11/24/2023Ownership: 0.001%View All Insider TransactionsView All Institutional Transactions Should I Buy Alnylam Pharmaceuticals Stock? ALNY Pros and Cons Explained These insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms. This analysis of Alnylam Pharmaceuticals was last updated on Tuesday, November 28, 2023 at 10:13 PM. Pros Here are some ways that investors could benefit from investing in Alnylam Pharmaceuticals, Inc.: Strong pipeline of investigational RNAi therapeutics targeting various diseases, including genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and CNS/ocular diseases. Marketed products such as ONPATTRO, GIVLAARI, and OXLUMO have shown promising results in treating specific conditions, providing potential revenue streams. Strategic collaborations with Regeneron Pharmaceuticals, Sanofi Genzyme, and other companies enhance the company's research and development capabilities and market reach. Ongoing clinical trials for products like givosiran, patisiran, and vutrisiran offer potential for future product approvals and market expansion. Recent positive developments and partnerships indicate a strong growth trajectory for the company. Cons Investors should be bearish about investing in Alnylam Pharmaceuticals, Inc. for these reasons: The biopharmaceutical industry is highly competitive and subject to regulatory challenges, which may impact the company's ability to bring products to market. Investing in biopharmaceutical companies carries inherent risks, including clinical trial failures, regulatory setbacks, and intellectual property disputes. Market volatility and economic uncertainties can affect the company's stock price and overall financial performance. Dependency on successful product launches and commercialization efforts for revenue generation. Potential impact of healthcare reforms and changes in reimbursement policies on the company's financials. ALNY Stock Analysis - Frequently Asked Questions Should I buy or sell Alnylam Pharmaceuticals stock right now? 19 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Alnylam Pharmaceuticals in the last twelve months. There are currently 6 hold ratings and 13 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" ALNY shares. View ALNY analyst ratings or view top-rated stocks. What is Alnylam Pharmaceuticals' stock price target for 2024? 19 equities research analysts have issued 12 month target prices for Alnylam Pharmaceuticals' stock. Their ALNY share price targets range from $143.00 to $395.00. On average, they predict the company's share price to reach $233.00 in the next twelve months. This suggests a possible upside of 34.8% from the stock's current price. View analysts price targets for ALNY or view top-rated stocks among Wall Street analysts. How have ALNY shares performed in 2023? Alnylam Pharmaceuticals' stock was trading at $237.65 at the beginning of the year. Since then, ALNY shares have decreased by 27.3% and is now trading at $172.87. View the best growth stocks for 2023 here. When is Alnylam Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, February 22nd 2024. View our ALNY earnings forecast. How were Alnylam Pharmaceuticals' earnings last quarter? Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) announced its earnings results on Thursday, November, 2nd. The biopharmaceutical company reported $1.15 EPS for the quarter, beating the consensus estimate of ($1.61) by $2.76. The biopharmaceutical company had revenue of $750.53 million for the quarter, compared to the consensus estimate of $406.14 million. What ETFs hold Alnylam Pharmaceuticals' stock? ETFs with the largest weight of Alnylam Pharmaceuticals (NASDAQ:ALNY) stock in their portfolio include Morningstar US Small Growth (MSGR), ETFMG Treatments Testing and Advancements ETF (GERM), Global X Genomics & Biotechnology ETF (GNOM), First Trust NYSE Arca Biotechnology Index Fund (FBT), Horizon Kinetics Medical ETF (MEDX), VanEck Biotech ETF (BBH), Fidelity Disruptive Medicine ETF (FMED) and Principal Healthcare Innovators ETF (BTEC). What is John M. Maraganore's approval rating as Alnylam Pharmaceuticals' CEO? 65 employees have rated Alnylam Pharmaceuticals Chief Executive Officer John M. Maraganore on Glassdoor.com. John M. Maraganore has an approval rating of 99% among the company's employees. This puts John M. Maraganore in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Alnylam Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Alnylam Pharmaceuticals investors own include Alibaba Group (BABA), NVIDIA (NVDA), XOMA (XOMA), Ionis Pharmaceuticals (IONS), Gilead Sciences (GILD), NXP Semiconductors (NXPI), Mylan (MYL), AbbVie (ABBV), Micron Technology (MU) and Advanced Micro Devices (AMD). Who are Alnylam Pharmaceuticals' major shareholders? Alnylam Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional shareholders include Baillie Gifford & Co. (6.51%), Wellington Management Group LLP (5.13%), Northern Trust Corp (0.64%), Legal & General Group Plc (0.63%), Ameriprise Financial Inc. (0.56%) and Massachusetts Financial Services Co. MA (0.55%). Insiders that own company stock include Akshay Vaishnaw, Indrani Lall Franchini, Jeffrey V Poulton, Jeffrey W Dunn, John Maraganore, Laurie Keating, Pushkal Garg, Steven M Paul, Tolga Tanguler and Yvonne Greenstreet. View institutional ownership trends. How do I buy shares of Alnylam Pharmaceuticals? Shares of ALNY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. This page (NASDAQ:ALNY) was last updated on 12/4/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Alnylam Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.